Dr Reddy’s Lab surges on launching Fenofibrate Capsules

Dr. Reddys Laboratories is currently trading at Rs. 2610.00, up by 44.55 points or 1.74% from its previous closing of Rs. 2565.45 on the BSE. The scrip opened at Rs. 2584.00 and has touched a high and low of Rs. 2612.00 and Rs. 2584.00 respectively. So far 8312 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2939.80 on 28-Feb-2014 and a 52 week low of Rs. 1914.90 on 25-Apr-2013. Last one week high and low of the scrip stood at Rs. 2612.00 and Rs. 2524.75 respectively. The current market cap of the company is Rs. 44338.88 crore. The promoters holding in the company stood at 25.52% while Institutions and Non-Institutions held 40.59% and 15.87% respectively. Dr Reddy’s Laboratories has launched Fenofibrate Capsules, USP 43 mg and 130 mg a therapeutic equivalent generic version of ANTARA (fenofibrate) capsules, in the US market on April 22, 2014, approved by the United States Food & Drug Administration (USFDA). The ANTARA (fenofibrate) capsules brand and generic had U.S. sales of approximately $74 Million MAT for the most recent twelve months ending in February 2014 according to IMS Health. The company’s Fenofibrate capsules, USP 43 mg is available in bottle counts of 30 and 130 mg are available in bottle counts of 30 and 90. Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.